Ascendis (ASND) Q3 2026 Earnings Call Transcript
Ascendis (ASND) reported Q3 2026 product revenue of €366 million, up 89% YoY. Key drivers: growth in existing products (Yorvipath, Yuvivel, Skytrofa), indication expansions, and new products. Yorvipath revenue was €291 million, up 103% YoY. Yuvivel and Skytrofa also showed strong demand. The company aims for €5 billion in annual revenue by 2030.
How this was made

The 30-second read
Why it matters
The strong revenue growth and pipeline progress provide a fresh catalyst for the stock.
Market read
First report of Q3 earnings with significant revenue growth, offering actionable insight for traders.
What to watch
Potential regulatory delays for upcoming label extensions could temper growth.
Background
Ascendis Pharma held its Q3 2026 earnings call, presenting revenue and pipeline updates.
Ticker impact
Q3 2026 product revenue of €366 million, up 89% year over year, indicating strong growth.
likely upward pressure as market prices in strong revenue growth
Revenue growth far exceeds prior year and quarter, providing fresh positive catalyst.
Market effects
Biopharma sector may see broader optimism from Ascendis' growth.
European markets could benefit from the strong Euro‑denominated revenue.
Highlights demand for rare‑disease therapies worldwide.
Counterpoint
If guidance falls short of expectations, the stock could face a pullback despite revenue beat.
Key entities
- CompanyAscendis Pharma
US‑listed biopharma company (ASND).
